Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Dermatology
Published in: BMC Dermatology 1/2012

Open Access 01-12-2012 | Research article

Trends in lipid profiles in patients with psoriasis: a population-based analysis

Authors: Bharath Manu Akkara Veetil, Eric L Matteson, Hilal Maradit-Kremers, Marian T McEvoy, Cynthia S Crowson

Published in: BMC Dermatology | Issue 1/2012

Login to get access

Abstract

Background

Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.

Methods

We compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.

Results

There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.

Conclusions

Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.
Appendix
Available only for authorised users
Literature
1.
Kremers HM, McEvoy MT, Dann FJ, Gabriel SE: Heart disease in psoriasis. J Am Acad Dermatol 2007, 57: 347–354. 10.1016/j.jaad.2007.02.007CrossRefPubMed
2.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM: Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010, 31: 1000–1006. 10.1093/eurheartj/ehp567CrossRefPubMed
3.
Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, et al.: Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology (Basel, Switzerland) 2008, 217: 27–37. 10.1159/000121333CrossRef
4.
Kimball AB, Wu Y: Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 2009, 48: 1147–1156. 10.1111/j.1365-4632.2009.04075.xCrossRefPubMed
5.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F: Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry 2001, 303: 33–39. 10.1016/S0009-8981(00)00358-2CrossRefPubMed
6.
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD: Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008, 88: 561–565.PubMed
7.
Tekin NS, Tekin IO, Barut F, Sipahi EY: Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007, 2007: 78454.PubMed
8.
Farshchian M, Zamanian A, Monsef AR, Mahjub H: Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007, 21: 802–805. 10.1111/j.1468-3083.2006.02099.xCrossRefPubMed
9.
Vahlquist C, Michaelsson G, Vessby B: Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987, 67: 12–15.PubMed
10.
11.
Maradit Kremers H, Crowson CS, Gabriel SE: Rochester epidemiology project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am 2004, 30: 819–834. vii. 10.1016/j.rdc.2004.07.010CrossRefPubMed
12.
Maradit Kremers H, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL: The rochester epidemiology project: exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology (Oxford) 2011, 50: 6–15. 10.1093/rheumatology/keq199CrossRef
13.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285: 2486–2497. 10.1001/jama.285.19.2486CrossRef
14.
Piskin S, Gurkok F, Ekuklu G, Senol M: Serum lipid levels in psoriasis. Yonsei Med J 2003, 44: 24–26.CrossRefPubMed
15.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006, 298: 321–328. 10.1007/s00403-006-0703-zCrossRefPubMed
16.
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG: Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009, 145: 700–703. 10.1001/archdermatol.2009.94CrossRefPubMed
17.
Gelfand JM, Mehta NN, Langan SM: Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011, 131: 1007–1010. 10.1038/jid.2011.32CrossRefPubMedPubMedCentral
18.
Third Report of the National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106: 3143–3421.
19.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55: 829–835. 10.1016/j.jaad.2006.08.040CrossRefPubMed
20.
Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE: Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69: 1310–1314. 10.1136/ard.2009.122374CrossRefPubMed
21.
Prodanovich S, Shelling ML, Federman DG, Kirsner RS: Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases. Arch Dermatol 2008, 144: 1518–1519. 10.1001/archderm.144.11.1518CrossRefPubMed
22.
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352: 1685–1695. 10.1056/NEJMra043430CrossRefPubMed
23.
Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ: More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161: 1–7.CrossRefPubMed
24.
White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, et al.: Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years’ experience. J Clin Epidemiol 1996, 49: 223–233. 10.1016/0895-4356(95)00041-0CrossRefPubMed
25.
Akgun S, Ertel NH, Mosenthal A, Oser W: Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 1998, 131: 103–108. 10.1016/S0022-2143(98)90083-XCrossRefPubMed
26.
Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al.: Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005, 294: 1773–1781. 10.1001/jama.294.14.1773CrossRefPubMed
Metadata
Title
Trends in lipid profiles in patients with psoriasis: a population-based analysis
Authors
Bharath Manu Akkara Veetil
Eric L Matteson
Hilal Maradit-Kremers
Marian T McEvoy
Cynthia S Crowson
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Dermatology / Issue 1/2012
Electronic ISSN: 1471-5945
DOI
https://doi.org/10.1186/1471-5945-12-20

Other articles of this Issue 1/2012

BMC Dermatology 1/2012 Go to the issue

Research article

What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial

Correspondence

Tips and tricks in the dermoscopy of pigmented lesions

Study protocol

Chronic hand eczema - self-management and prognosis: a study protocol for a randomised clinical trial

Research article

Characterization of a unique technique for culturing primary adult human epithelial progenitor/“stem cells”

Research article

The treatment of melasma by silymarin cream

Research article

Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort